Evidence map›Paper›PMID 29619533›Full record

Trial reportPsychopharmacology2018

The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.

Douglas L Boggs, Toral Surti, Aarti Gupta, Swapnil Gupta, Mark Niciu, Brian Pittman, Ashley M Schnakenberg Martin, Halle Thurnauer, Andrew Davies, Deepak C D'Souza and 1 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Psychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00588731 (Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia), which is not on this map. Cited by 115 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 12 pooled it
19.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00588731 phase2completednot on this map

Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia

TypeinterventionalSponsorYale UniversityRan2009 to 2013Enrolled41ConditionsSchizophrenia, Schizoaffective DisorderArmsCannabidiol, Placebo
3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 12 syntheses or guidelines pooled it, 231 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Multinational Association of Supportive Care in Cancer (MASCC) guidelines: cannabis for psychological symptoms including insomnia, anxiety, and depression.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. A systematic review of cannabidiol dosing in clinical populations.British journal of clinical pharmacology · 2019
    Pooled it
  12. Pooled it
  13. Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Acute effects of ΔPsychopharmacology · 2022
    Trial

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Douglas L BoggsSchizophrenia and Neuropharmacology Research Group at Yale, VA Connecticut Healthcare System, West Haven, CT, USA.
Toral SurtiSchizophrenia and Neuropharmacology Research Group at Yale, VA Connecticut Healthcare System, West Haven, CT, USA.
Aarti GuptaSchizophrenia and Neuropharmacology Research Group at Yale, VA Connecticut Healthcare System, West Haven, CT, USA.
Swapnil GuptaSchizophrenia and Neuropharmacology Research Group at Yale, VA Connecticut Healthcare System, West Haven, CT, USA.
Mark NiciuExperimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, Bethesda, MD, USA.
Brian PittmanDepartment of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Ashley M Schnakenberg MartinSchizophrenia and Neuropharmacology Research Group at Yale, VA Connecticut Healthcare System, West Haven, CT, USA.
Halle ThurnauerSchizophrenia and Neuropharmacology Research Group at Yale, VA Connecticut Healthcare System, West Haven, CT, USA.
Andrew DaviesGW Pharmaceuticals, Cambridge, UK.
Deepak C D'SouzaSchizophrenia and Neuropharmacology Research Group at Yale, VA Connecticut Healthcare System, West Haven, CT, USA.
Mohini RanganathanSchizophrenia and Neuropharmacology Research Group at Yale, VA Connecticut Healthcare System, West Haven, CT, USA. Mohini.Ranganathan@yale.edu.
Connecticut Mental Health Center · USYale University · USGW Pharmaceuticals (United Kingdom) · GBNational Institute of Mental Health · USVA Connecticut Healthcare System · US

Funding

Stanely Medical Research Institute 07TGS-1082
6 · The paper itself

Abstract

rationalePreliminary evidence suggests that cannabidiol (CBD) may be effective in the treatment of neurodegenerative disorders; however, CBD has never been evaluated for the treatment of cognitive impairments associated with schizophrenia (CIAS).

objectiveThis study compared the cognitive, symptomatic, and side effects of CBD versus placebo in a clinical trial.

methodsThis study was a 6-week, randomized, placebo-controlled, parallel group, fixed-dose study of oral CBD (600 mg/day) or placebo augmentation in 36 stable antipsychotic-treated patients diagnosed with chronic schizophrenia. All subjects completed the MATRICS Consensus Cognitive Battery (MCCB) at baseline and at end of 6 weeks of treatment. Psychotic symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS) at baseline and biweekly.

resultsThere was no main effect of time or drug on MCCB Composite score, but a significant drug × time effect was observed (p = 0.02). Post hoc analyses revealed that only placebo-treated subjects improved over time (p = 0.03). There was a significant decrease in PANSS Total scores over time (p < 0. 0001) but there was no significant drug × time interaction (p = 0.18). Side effects were similar between CBD and placebo, with the one exception being sedation, which was more prevalent in the CBD group.

conclusionsAt the dose studied, CBD augmentation was not associated with an improvement in MCCB or PANSS scores in stable antipsychotic-treated outpatients with schizophrenia. Overall, CBD was well tolerated with no worsening of mood, suicidality, or movement side effects.

trial registrationhttps://clinicaltrials.gov/ct2/show/NCT00588731.

Indexed as

Schizophrenic PsychologyAdministration, OralAdultAffectAntipsychotic AgentsCannabidiolChronic DiseaseCognitionCognitive DysfunctionDouble-Blind MethodFemaleFollow-Up StudiesHumansMaleMental Status and Dementia TestsMiddle AgedAntipsychotic AgentsCannabidiolAttentionCannabidiolCannabinoidsCBDCognitionMemoryPsychosisSchizophrenia

Identifiers

PMID29619533
OpenAlexW2795424865

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.